Search results

Page results

• National leadership award for UCLH research practitioner

  UCLH research manager Sarah Taylor has won a national leadership award for her work to develop and train research staff.

• National dementia research role for UCLH clinician

  UCLH consultant neurologist Dr Catherine Mummery has been announced as the new Chair of the NIHR Dementia Translational Research Collaboration.

• SUMMIT Study catches up with pre-pandemic follow up appointments

  As World Lung Cancer Day approaches (1 August) the SUMMIT Study reports that it has made great strides in catching up with patients whose nodule follow ups were cancelled due to COVID-19.

• Biatain® dressings for radiotherapy and proton beam therapy skin reactions

  Patient information who have been recommended to use a Biatain® dressing on your skin that has broken down due to your radiotherapy or proton beam therapy treatment.

• Thoracic Surgery – Information for patients: Having a thymectomy procedure

  Patient information for patients having a thymectomy procedure.

• Thoracic Surgery – Information for patients: Having surgery via median sternotomy

  Information for patients having a surgery via median sternotomy.

• Thoracic Surgery – Information for patients: Having a mediastinoscopy / mediastinotomy procedure

  Information for patients having a mediastinoscopy / mediastinotomy procedure.

• What is acute myeloid leukaemia (AML)?

  Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.

• National Hospital for Neurology and Neurosurgery anaesthetists rewarded for high-quality patient care

  The National Hospital for Neurology and Neurosurgery (NHNN), part of UCLH NHS Foundation Trust, has been reaccredited under the prestigious Royal College of Anaesthetists (RCoA) Anaesthesia Clinical Services Accreditation (ACSA) demonstrating the hospital anaesthetists’ commitment to patient safety and excellence of care.

• Treating acute myeloid leukaemia (AML)

  Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.